Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DeCode moves artery disease treatment into phase II
The company has begun patient enrollment in a phase IIa trial that will examine safety and tolerability, dosing, and the effect of different dose levels on platelet function
The company has begun patient enrollment in a phase IIa trial that will examine safety and tolerability, dosing, and the effect of different dose levels on platelet function
During the trial, hypogonadal men, receive Nebido via intramuscular injection every 12 weeks. The primary endpoint in the pharmacokinetic trial is the assessment of average serum testosterone levels
Avigen is developing AV650 in the North American market under a license and supply agreement with Sanochemia Pharmazeutika AG. The compound is already marketed in Europe and Asia
According to results, presented by the company at the Annual European Congress of Rheumatology in Amsterdam, the compound significantly reduced disease activity, exhibited clinically relevant bioactivity, and was
Under the two-year agreement, Innovex will provide contract sales, marketing, and commercialization services, including sales representative recruitment, sales force automation and sample accountability services, promotional education programs and
The results were presented at the European League against Rheumatism (EULAR) 2006 Annual Congress in Amsterdam. The response rate, defined as the proportion of patients that had a
The open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of the antibody, CR011-vcMMAE, for patients with unresectable stage III or stage IV melanoma who have
The approved protocol is designed to test the safety, immunological and antiviral effects of AMZ0026, Amazon Biotech’s anti-HIV parent formula. The double-blind, placebo-controlled clinical trial design involves 32
The new Brazilian subsidiary, Schering-Plough Produtos Farmaceuticos Limitada, will assume commercial responsibility for Schering-Plough specialty care products, including Peg-intron, Temodal and Caelyx. The company also will market the
The results showed that Velcade in combination with melphalan and prednisone (V-MP) appeared significantly superior to melphalan and prednisone (MP) alone in treating elderly patients with newly diagnosed